Neurocrine Biosciences, Inc <NBIX.O>: Piper Sandler raises target price to $210 from $207
NBIX•Related News
HSBC survey shows affluent investors cut cash allocation to 19% in 2026 from 33% in 2024
HSBC•
Reddit <RDDT.N>: Jefferies cuts target price to $225 from $250
RDDT•
Guardant Health Inc <GH.O>: JPMorgan Raises Target Price to $195 From $185
GH•
HSBC sells $25 billion Australian loan portfolio to Blackstone
HSBC•
Dexcom Inc <DXCM.O>: JPMorgan raises target price to $82 from $65
DXCM•